Suppr超能文献

伽玛刀放射外科治疗伴门静脉癌栓肝细胞癌的耐受性和疗效

Tolerability and efficacy of gamma knife radiosurgery on hepatocellular carcinoma with portal vein tumor thrombosis.

作者信息

Lu Xiao-Jie, Dong Jing, Ji Li-Juan, Xiao Li-Xin, Ling Chang-Quan, Zhou Jun

机构信息

Department of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.

Outpatient Department, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang Province, China.

出版信息

Oncotarget. 2016 Jan 19;7(3):3614-22. doi: 10.18632/oncotarget.6118.

Abstract

This is a retrospective study on the safety and efficacy of gamma knife radiosurgery (GKR) in treating hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). Patients with confirmed HCC and PVTT were allocated into two groups based on the treatments they received (palliative or GKR). A total of 138 patients were included (74 in the palliative group, 64 in GKR group). No significant differences in baseline characteristics existed between the two groups. Treatment-related adverse events (AEs) were recorded and compared between groups. The majority of AEs were mild to moderate and subsided naturally or after medication. There was no AE-induced death. The influences of baseline characteristics and treatment options on patients' OS were analyzed. The median OS of patients in the palliative and GKR group were 3.0 months (95% CI: 2.719-3.281) and 6.1 months (95% CI: 4.706-7.494) respectively (p = 0.003). Multivariate analysis revealed that GKR treatment, performance status 0-1, Child A, smaller tumor diameter and monolobar distribution were significant favorable prognosticators. Subgroup analyses showed OS benefit of GKR regardless of PVTT location (main or branch of PVTT). In conclusion, GKR is well tolerated in selected HCC-PVTT patients and can confer OS benefit, which needs validation in future prospective studies.

摘要

这是一项关于伽玛刀放射外科治疗(GKR)伴有门静脉癌栓(PVTT)的肝细胞癌(HCC)的安全性和有效性的回顾性研究。确诊为HCC和PVTT的患者根据其接受的治疗(姑息治疗或GKR)分为两组。共纳入138例患者(姑息治疗组74例,GKR组64例)。两组之间的基线特征无显著差异。记录并比较两组之间与治疗相关的不良事件(AE)。大多数AE为轻度至中度,自然消退或经药物治疗后消退。没有AE导致的死亡。分析了基线特征和治疗方案对患者总生存期(OS)的影响。姑息治疗组和GKR组患者的中位OS分别为3.0个月(95%CI:2.719-3.281)和6.1个月(95%CI:4.706-7.494)(p=0.003)。多因素分析显示,GKR治疗、体能状态0-1、Child A级、较小的肿瘤直径和单叶分布是显著的有利预后因素。亚组分析显示,无论PVTT位置(PVTT主干或分支)如何,GKR都能带来OS获益。总之,GKR在选定的HCC-PVTT患者中耐受性良好,可带来OS获益,这需要在未来的前瞻性研究中得到验证。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49b0/4823131/5bd8be92696b/oncotarget-07-3614-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验